|Bid||0.00 x 2900|
|Ask||6.21 x 1000|
|Day's Range||5.22 - 5.43|
|52 Week Range||4.71 - 15.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
NEW YORK, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion ...
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources - - Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 ...
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.
The call will provide an update on Merrimack's recent progress as well as a summary of its second quarter 2018 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.
Two former employees of rival biopharmaceutical companies were convicted on Tuesday on U.S. charges that they used their access to confidential information about drug studies to profit in the stock market through insider trading. A federal jury in Boston found Schultz Chan, a former Akebia Therapeutics Inc employee, and Songjiang Wang, who worked at Merrimack Pharmaceuticals Inc, guilty on conspiracy and securities fraud charges. Prosecutors said that from 2013 to 2014, Wang, Merrimack's director of statistical programming, tipped his friend Chan, 54, three times about positive results in drug studies before the Cambridge, Massachusetts-based company announced them.
CAMBRIDGE, Mass., July 2, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the closing of a $25 million term loan with Hercules Capital (HTGC), $15 million of which was funded at closing today. Merrimack's current cash and cash equivalents, including the $15 million of loan proceeds received, and certain potential net milestone payments anticipated from Shire are projected to fund the company's planned operations into the first quarter of 2020. "This non-dilutive financing strengthens Merrimack's financial position, allowing us to remain focused on advancing the discovery, clinical and business development efforts for our nine wholly-owned programs in development, including our two clinical readouts expected later this year from MM-121 and MM-310," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack.
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.
A former Akebia Therapeutics Inc (AKBA.O) employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday. U.S. District Judge Indira Talwani in Boston ordered the detention of Schultz Chan, who has had prior issues following court directives, after asking why he could not heed her warnings to not talk to witnesses, as he did by saying hello to one. The development occurred shortly after jurors heard opening statements in the trial of Chan and Songjiang Wang, a former Merrimack Pharmaceuticals Inc (MACK.O) employee who prosecutors say participated in the insider trading scheme with Chan.
Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.
Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial. The company said it would now focus on developing other programs in its pipeline, which includes a drug for breast cancer and lung cancer. The experimental pancreatic cancer treatment, MM-141, was being studied in addition to standard-of-care treatment for patients with previously untreated metastatic pancreatic cancer.
Merrimack Pharmaceuticals Inc. (mack) said Monday a midstage trial of a treatment for pancreatic cancer failed to meet its main goals. The clinical-stage oncology company said results from a Phase 2 trial that added MM-141 to the current treatments for patients with previously untreated metastatic pancreatic cancer and high serum levels of free Insulin-like Growth Factor-1 failed to meet its primary and secondary endpoints. The company said it will not devote any more resources to the development of MM-141, but will continue with two clinical programs, MM-121 and MM-310, with data expected later in 2018.
- CARRIE study did not meet primary or secondary endpoints - - Company ceases development of MM-141 - - Focus remains on advancing Merrimack's promising clinical and preclinical pipeline, with two additional ...
Investors in Merrimack Pharmaceuticals (MACK) need to pay close attention to the stock based on moves in the options market lately.
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AngioDynamics, ...
CAMBRIDGE, Mass., May 29, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018 at McCormick Place North/South in Chicago. A poster with an analysis of pharmacokinetic and safety data comparing different dosing regimens from nine previous Phase 1 and Phase 2 studies of seribantumab in solid tumors will be presented. Seribantumab is Merrimack's wholly-owned, fully human monoclonal antibody targeting HER3 (ErbB3).
- Three clinical readouts expected in 2018, including data from two randomized Phase 2 studies - - Conference call at 8:30 am ET today - CAMBRIDGE, Mass. , May 8, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, ...
The company will provide an update on Merrimack's recent progress as well as a summary of first quarter 2018 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.